Posts by: Vijaya Iyer

cystic fibrosis, News

Blocking the enzyme cathepsin S can alleviate symptoms and reduce lung damage in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), according to multinational teams led by researchers at Queen’s ... Read more

March 11, 2019March 11, 2019

ContraFect Granted Up to $6.94M to Develop Novel Therapy Against ESKAPE Pathogens

cystic fibrosis, News

ContraFect will receive up to $6.94 million in funding from CARB-X to support the development of their proprietary therapeutic peptides — amurins — against antibiotic-resistant bacterial infections caused by gram-negative ESKAPE ... Read more

March 5, 2019March 5, 2019

MaRS Innovation Supports LAB150 Research on New Therapeutics for CF and Other Conditions

cystic fibrosis, News

MaRS Innovation recently announced the launch of two new projects targeting the development of new therapeutics for cystic fibrosis (CF) and respiratory syncytial virus (RSV). These projects are part of LAB150, ... Read more

February 28, 2019March 15, 2019

CF Market Research Report Includes Patients’ and Caregivers’ Perspectives

cystic fibrosis, News

NetNoggin has launched a new cystic fibrosis (CF) market research report to highlight patient and caregiver experiences and their perspectives about the gaps in CF research, the company announced. NetNoggin ... Read more

February 14, 2019February 27, 2019

Cisco and Emily’s Hope Raise Over $1 Million in CFF’s Great Strides Campaign

cystic fibrosis, News

Emily’s Hope and Cisco have raised more than $1 million as part of Great Strides – a Cystic Fibrosis Foundation (CFF) fundraiser – becoming its top-performing national corporate team for the ... Read more

February 8, 2019February 20, 2019

Enrollment Info Updated on Phase 3 Trial Assessing AeroVanc for MRSA Infection in CF

cystic fibrosis, News

Enrollment for a Phase 3 clinical trial testing AeroVanc in patients with cystic fibrosis with methicillin-resistant Staphylococcus aureus (MRSA) lung infections is expected to be completed in the third quarter of ... Read more

January 18, 2019January 29, 2019

Non-invasive Ventilation Improves Lung Function in CF Patients But Not Survival, Study Finds

cystic fibrosis, News

A reassessment of U.K. medical records showed that in cystic fibrosis (CF) patients, breathing support provided by gas inhalation, through a face or nasal mask, helps improve lung function ... Read more

January 9, 2019January 16, 2019

Alcresta’s Relizorb Given Medicare/Medicaid Billing Code for Easier Claims

cystic fibrosis

The Centers for Medicare and Medicaid Services (CMS) has issued a permanent billing code (B4105) to Alcresta Therapeutics’ in-line digestive enzyme cartridge Relizorb, making it easier for insurance payers ... Read more

January 3, 2019January 11, 2019

Vertex to Request Review of Orkambi, Symkevi Plus Kalydeco for Public Funding in Scotland

cystic fibrosis

Vertex Pharmaceuticals has announced its intention to submit an application to the Scottish Medicines Consortium (SMC) to review the clinical and cost-effectiveness of the company’s cystic fibrosis (CF) medicines, Orkambi (lumacaftor/ivacaftor), as well ... Read more

November 6, 2018November 6, 2018

#NACFC2018 – RPL554 Shows Promising Results in CF Studies

cystic fibrosis, News

Positive data from preclinical and Phase 2a studies evaluating the investigational cystic fibrosis (CF) treatment RPL554 were presented at the 2018 North American Cystic Fibrosis Conference (NACFC) in Denver, Colorado (Oct. ... Read more

Posts by: Vijaya Iyer

Vijaya Iyer

Lung Enzyme Cathepsin S is New Therapeutic Target for CF and COPD

ContraFect Granted Up to $6.94M to Develop Novel Therapy Against ESKAPE Pathogens

MaRS Innovation Supports LAB150 Research on New Therapeutics for CF and Other Conditions

CF Market Research Report Includes Patients’ and Caregivers’ Perspectives

Cisco and Emily’s Hope Raise Over $1 Million in CFF’s Great Strides Campaign

Enrollment Info Updated on Phase 3 Trial Assessing AeroVanc for MRSA Infection in CF

Non-invasive Ventilation Improves Lung Function in CF Patients But Not Survival, Study Finds

Alcresta’s Relizorb Given Medicare/Medicaid Billing Code for Easier Claims

Vertex to Request Review of Orkambi, Symkevi Plus Kalydeco for Public Funding in Scotland

#NACFC2018 – RPL554 Shows Promising Results in CF Studies

Pin It on Pinterest